Janssen

BEERSE, Belgium, October 21, 2011 - New data presented at EADV New findings from the TRANSIT study were presented today at the 20th European Academy of Dermatology and Venereology (EADV) congress, which showed treatment with STELARA (ustekinumab) is well-tolerated and effective in patients with moderate to severe plaque psoriasis inadequately responsive to methotrexate therapy.[1] Health-related quality of life was also significantly improved according to the study results reported.[2] The TRANSIT study, a 52 week, open-label, phase IV study of 489 patients, was designed to compare two methods of transitioning patients from methotrexate to ustekinumab.

HIGH WYCOMBE, England, October 21, 2011 - New Data Presented at EADV New findings from the TRANSIT study were presented today at the 20th European Academy of Dermatology and Venereology (EADV) congress, which showed treatment with STELARA[▼](ustekinumab) is well-tolerated and effective in patients with moderate-to-severe plaque psoriasis inadequately responsive to methotrexate therapy.[1] Health-related quality of life was also noticeably improved according to the study results reported.[2] The TRANSIT study, a 52 week, open-label, phase IV study of 489 patients, was designed to compare two methods of transitioning patients from methotrexate to ustekinumab.

BEERSE, Belgium, September 7, 2011 - First once-daily, oral treatment inhibits androgen production at all sources Janssen-Cilag International NV announced today that, after an accelerated regulatory review process by the European Medicines Agency (EMA) and following a positive CHMP opinion on the 22 July 2011, the European Commission has approved the marketing authorisation for ZYTIGA (abiraterone acetate), a novel, once-daily, oral, androgen biosynthesis inhibitor.

BEERSE, Belgium, July 22, 2011 - Janssen-Cilag International NV announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of ZYTIGA (abiraterone acetate) under an accelerated regulatory review procedure.

CHICAGO and BEERSE, Belgium, June 6, 2011 - - Data From DACO-016 Trial at 2011 American Society of Clinical Oncology Annual Meeting - NB: Data in this release corresponds to ASCO abstract 6504 Data from the DACO-016 trial of DACOGEN(R) (decitabine) presented today at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), demonstrate a clinically significant improvement in overall survival in older patients with newly diagnosed de novo or secondary acute myeloid leukemia (AML) as defined by the World Health Organisation (WHO).[1] AML is a life-threatening disease that affects primarily older adults; very limited treatment options exist.